CELU Celularity Inc.
Debt Financing ·
Celularity sold about $11.01 million of notes that convert at $1.50 a share, with warrants for about 4,037,000 shares. A second tranche of up to $10.0 million is available at the buyers' election through September 30, 2027.
Celularity (Nasdaq: CELU) was told on July 23, 2026 that its Class A common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its listing, the company says.
Celularity signed a $1,000,000 secured loan with the Philip & Daniele Barach Family Trust at 4.0%. The loan matures at the earlier of 30 days after closing or receipt of certain financing proceeds, and it rises to 18.0% after a default.
Nasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock.
Nasdaq told Celularity on September 2, 2025 that it complies with Listing Rule 5250(c)(1) again, after the company filed its Form 10-Q reports for the periods ended March 31 and June 30, 2025.
Celularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $26.6 million | $54.2 million |
| Research and development | $15.0 million | $17.4 million |
| Net income (loss) | -$91.7 million | -$57.9 million |
| Cash from operations | -$13.3 million | -$6.4 million |
| Cash and equivalents | $6.2 million | $738,000 |
Our latest story on this, dated Jun 12, 2026: "Celularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 28, 2026: "Celularity sells $11.01 million of secured convertible notes in deal of up to $25.0 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 29, 2026: "Celularity gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027 to comply". The story links the filing or release it is based on. Read the story.
Celularity Inc. trades under the ticker CELU on NASDAQ.
Celularity Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Celularity Inc. is 1752828. Its filings are on SEC EDGAR.
32,450,679 shares as of 2026-10-19, per the cover page of its 10-Q filed 2026-10-20.
Our directory records Celularity Inc. under United States.
Our directory classifies Celularity Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Celularity Inc. is US1511902041.
aibio.space lists Celularity Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$26.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Celularity Inc. reported a net loss of $91.7 million for the fiscal year ended Dec 31, 2025, and used $13.3 million of cash in operations, per its annual report to the SEC.
$15.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.03,5.02,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio